Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Pulmicort

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Background Cystic fibrosis (CF) is a chronic, life-limiting disease caused by mutations in the CF transmembrane conductance… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
Meconium aspiration syndrome (MAS) triggers inflammatory and oxidative pathways which can inactivate both pulmonary surfactant… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
BACKGROUND Pulmonary rehabilitation (PR) is proposed as an effective strategy to decrease surgical morbidity. However… Expand
2011
2011
BACKGROUND Combination therapy with inhaled corticosteroids (ICS) and long-acting β(2)-adrenergic agonists (LABA) is reported to… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2009
2009
The electrical Next Generation Impactor (eNGI) was assessed against the electrical low-pressure impactor (ELPI) and next… Expand
  • figure 1
  • figure 5
  • figure 6
  • figure 7
  • figure 8
2005
2005
This study compared the in vitro performance of two inhaled corticosteroid products for nebulisation, Pulmicort Respules… Expand
Highly Cited
2004
Highly Cited
2004
The objective of this investigation was to study the relation between size and position of a mask leak on spacer output and lung… Expand
2003
2003
Although dry powder inhalers are well established for the delivery of corticosteroids, the pressurised metered dose inhaler… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
2003
2003
Assessment of adrenal suppression via systemic cortisol levels provides an indirect measure of the lung delivery of inhaled… Expand
Highly Cited
1998
Highly Cited
1998
Electrostatic charge in plastic spacer devices has been shown in vitro to reduce delivery of asthma medications intended for… Expand